Clinical Research Leader in Rheumatology
Minneapolis, United States
Currently serving as a consultant to a group medical care practice in Minneapolis, Minnesota, Dr. Brent Appleton sees patients suffering from conditions such as osteoporosis, Sjogren’s syndrome, rheumatoid arthritis, gout, and lupus. Having earned over 10 years of experience in clinical development for global biotechnology companies, Dr. Brent Appleton previously served as clinical development senior director for the immunoregulatory program at Dynavax Technologies and in a leadership role for an interstitial pulmonary fibrosis (IPF) program at Gilead Sciences, Inc. While with Gilead, Dr. Appleton implemented improvements to optimize the design of a phase 3 IPF clinical trial and led a team in the evaluation of potential partnerships with global contract research organizations. Beyond his work as a clinical consultant and a pharmaceutical researcher, Dr. Brent Appleton has also spoken before academic audiences on issues related to rheumatic diseases. At the University of Michigan Health System Division of Rheumatology, he served as a lecturer and earned the Thomas D. Palella Excellence in Teaching Award. As a participant in rheumatology journal clubs, he has given presentations on etanercept therapy in rheumatoid arthritis and recombinant human relaxin in the treatment of scleroderma. A fellow of the American College of Rheumatology, Dr. Brent Appleton possesses a license to practice medicine in eight US states. He is a recipient of the National Arthritis Foundation Physician Scientist Award.